Sciclone Pharmaceuticals is a specialty pharmaceutical company focused on developing and marketing products to treat oncology, infectious diseases and urology.
The company’s strategy is to in-license new or differentiated products then market them to the patients of China. Over the years and with a decade of commercial experience the company has brought in some big products from the top 50 pharmaceutical companies.
In 2012 SciClone Pharmaceuticals had pain treatment Tramadol approved for marketing in China and now the company is working with BTG/Biocompatibles to potentially market the product DC Bead which delivers chemotherapy drugs to liver cancer tumours. Other products on the development table are Zensin’s Neucardin for chronic heart failure and Bioalliance’s Loramyc which is indicated for oropharyngeal candidiasis. With all these arrangements SciClone gain exclusive sales rights for China.
Although the company is focused in China, it actually based in the US this gives it a wide global reach and makes it easier to negotiate deals for US manufactured products.
SciClone also has its own flagship product ZADAXIN which is indicated for Hepatitis B, Hepatitis C and certain cancers. The product has been on the market some time having been approved back in the 1990’s.
Partnering to in-license
In order to build up its marketed portfolio in China, SciClone wishes to in-license further late stage clinical development products. The company is also interested in products that are approved in at least one of the big pharmaceutical markets or any differentiated products that are already marketed in China used in hospitals.
Andrew Wong, Vice President of Business development is the gentleman to contact for any potential deal discussions.
Since 2009 SciClone Pharmaceuticals announced 8 partnering / licensing deals, which is quite a lot more than many of the biotech companies currently at work out there.
SciClone Pharmaceuticals is routinely present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a small amount of time.
Events with SciClone Pharmaceuticals presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with SciClone Pharmaceuticals in person visit Current Partnering’s Event calendar.
Contacting SciClone Pharmaceuticals for partnering
SciClone Pharmaceuticals can be contacted in relation to partnering through a number of channels.
Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face discussions but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Sciclone’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual view the list of contacts at SciClone’s website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of SciClone’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit SciClone’s LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. SciClone Pharmaceuticals does not provide an online opportunity submission form.
SciClone Pharmaceuticals partnering at Current Agreements
Full details on each deal can be found at Current Agreements (subscription required)
Or purchase report: Partnering Agreements with SciClone Pharmaceuticals 2009-2014
Available reports from Current Partnering
Report: Partnering Agreements with SciClone Pharmaceuticals 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for SciClone Pharmaceuticals
Read: more on SciClone Pharmaceuticals company profile, recent partnering, M&A and financing news and articles
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering Insight Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering Insight M&A Scorecard – view top life science M&A deals by value
View: Current Partnering Insight Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering Insight Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk